Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Minerva Neurosciences, Inc. (NERV) is a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders, particularly conditions with significant unmet medical need in psychiatry and neurology. The company operates within the biotechnology and pharmaceutical research industry and does not have approved commercial products, with activities historically centered on drug discovery, clinical development, and regulatory advancement.
Minerva’s primary value has been driven by its proprietary CNS drug candidates, most notably roluperidone (MIN‑101), which has been investigated for the treatment of negative symptoms of schizophrenia. The company has positioned itself around addressing aspects of psychiatric illness that are poorly treated by existing therapies. Founded in 2007, Minerva was established by executives with prior CNS drug development experience and became a publicly traded company in 2014, using public capital markets to fund clinical research and development.
Business Operations
Minerva’s operations have historically consisted of a single operating segment focused on CNS drug development, encompassing preclinical research, clinical trials, regulatory engagement, and intellectual property management. The company has not generated product revenue and has relied on equity financing, collaboration payments, and cash reserves to fund operations.
Key assets have included roluperidone (MIN‑101) and earlier-stage or discontinued programs such as MIN‑202 (seltorexant) and MIN‑117, which were evaluated for sleep disorders and depression, respectively. Clinical trial execution has been conducted through a network of third-party research organizations across the United States and Europe. As of the most recent public disclosures, Minerva has had no material operating subsidiaries and limited internal manufacturing or commercialization infrastructure.
Strategic Position & Investments
Minerva’s strategic direction has centered on advancing differentiated CNS therapies through late-stage clinical development and seeking regulatory approval or strategic alternatives such as partnerships or asset monetization. The company previously entered into a collaboration involving seltorexant (MIN‑202), reflecting a strategy of leveraging partnerships with larger pharmaceutical companies to share development risk.
Following regulatory and clinical outcomes related to roluperidone (MIN‑101), the company disclosed that it was evaluating strategic alternatives, including restructuring, asset sales, or other corporate transactions. Public sources indicate that some development programs were discontinued after failing to meet clinical or regulatory endpoints. Where future development plans or long-term viability are concerned, data is inconclusive based on available public sources.
Geographic Footprint
Minerva Neurosciences is headquartered in Burlington, Massachusetts, with corporate functions centralized in the United States. Clinical development activities have historically extended across North America and Europe, reflecting the geographic distribution of clinical trial sites and regulatory engagement.
The company does not maintain significant physical operations outside the United States, and its international presence has primarily been limited to clinical research collaborations and trial management rather than commercial or manufacturing activities. Its global footprint is therefore best characterized as U.S.-based with international clinical reach.
Leadership & Governance
Minerva was founded by executives with extensive backgrounds in CNS drug development, and leadership has emphasized scientific rigor, targeted innovation, and capital discipline in high-risk therapeutic areas. Corporate governance follows standard U.S. public company practices, with oversight by a board of directors and compliance with SEC filings and disclosure requirements.
Key executives have included:
- Remy Luthringer, MD, PhD – Founder, President and Chief Executive Officer
- Joseph Reilly – Chief Financial Officer
- Hans-Gert Waldmann, MD – Chief Medical Officer (historical role during key development phases)
- Marc de Garidel – Chairman of the Board (during prior governance periods)
Leadership philosophy has been centered on developing mechanistically novel CNS treatments while pursuing partnerships or strategic alternatives to maximize shareholder value in a capital-intensive and high-risk sector.